NDAOTICSOLUTION/DROPS
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16m ago · AI intelligence enriched 16m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDESILON is a fixed-combination otic solution containing glacial acetic acid and desonide (a mild corticosteroid) for topical ear use. It is indicated for otitis externa and other inflammatory ear conditions where antimicrobial and anti-inflammatory activity is desired. The acetic acid provides antimicrobial action while desonide reduces inflammation in the external auditory canal.
LOE Approaching
This mature otic product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a consolidating team focused on defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRIDESILON offers limited career expansion given the mature, LOE-approaching lifecycle and zero linked job openings. Roles on this product are primarily focused on defending market share and managing generic transition rather than driving innovation or growth.
Brand ManagerField Sales Representative
Worked on TRIDESILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.